Compare Panacea Biotech with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs FULFORD INDIA - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH FULFORD INDIA PANACEA BIOTECH/
FULFORD INDIA
 
P/E (TTM) x 9.7 398.8 2.4% View Chart
P/BV x 3.8 6.2 60.7% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 PANACEA BIOTECH   FULFORD INDIA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-19
FULFORD INDIA
Mar-14
PANACEA BIOTECH/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs354942 37.5%   
Low Rs138450 30.7%   
Sales per share (Unadj.) Rs74.6691.4 10.8%  
Earnings per share (Unadj.) Rs6.711.5 58.3%  
Cash flow per share (Unadj.) Rs15.515.4 100.9%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs57.2380.0 15.1%  
Shares outstanding (eoy) m61.253.90 1,570.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.31.0 327.6%   
Avg P/E ratio x36.860.7 60.6%  
P/CF ratio (eoy) x15.945.3 35.0%  
Price / Book Value ratio x4.31.8 234.7%  
Dividend payout %017.4 0.0%   
Avg Mkt Cap Rs m15,0612,714 554.9%   
No. of employees `0002.30.4 521.2%   
Total wages/salary Rs m1,471505 291.2%   
Avg. sales/employee Rs Th1,973.66,073.0 32.5%   
Avg. wages/employee Rs Th635.61,137.4 55.9%   
Avg. net profit/employee Rs Th176.8100.7 175.6%   
INCOME DATA
Net Sales Rs m4,5672,696 169.4%  
Other income Rs m45125 35.7%   
Total revenues Rs m4,6122,822 163.4%   
Gross profit Rs m2,030-46 -4,374.4%  
Depreciation Rs m54015 3,552.6%   
Interest Rs m1,04810 11,034.7%   
Profit before tax Rs m48654 895.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7710 803.1%   
Profit after tax Rs m40945 915.2%  
Gross profit margin %44.4-1.7 -2,582.7%  
Effective tax rate %15.917.7 89.7%   
Net profit margin %9.01.7 540.4%  
BALANCE SHEET DATA
Current assets Rs m2,4151,738 138.9%   
Current liabilities Rs m9,077545 1,666.5%   
Net working cap to sales %-145.944.3 -329.6%  
Current ratio x0.33.2 8.3%  
Inventory Days Days6548 134.3%  
Debtors Days Days714 1,647.4%  
Net fixed assets Rs m8,33312 70,027.6%   
Share capital Rs m6139 157.2%   
"Free" reserves Rs m3,4431,443 238.6%   
Net worth Rs m3,5041,482 236.4%   
Long term debt Rs m4610-   
Total assets Rs m13,7552,077 662.4%  
Interest coverage x1.56.7 21.8%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.31.3 25.6%   
Return on assets %10.62.6 406.0%  
Return on equity %11.73.0 387.1%  
Return on capital %38.74.3 898.9%  
Exports to sales %20.90-   
Imports to sales %8.124.5 33.3%   
Exports (fob) Rs m954NA-   
Imports (cif) Rs m372659 56.4%   
Fx inflow Rs m1,20317 6,994.4%   
Fx outflow Rs m467673 69.3%   
Net fx Rs m736-656 -112.3%   
CASH FLOW
From Operations Rs m1,04990 1,165.3%  
From Investments Rs m-54105 -51.1%  
From Financial Activity Rs m-1,011-14 7,173.0%  
Net Cashflow Rs m-20181 -10.9%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.6 3.8 15.8%  
FIIs % 1.3 0.1 1,300.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 21.2 111.3%  
Shareholders   10,259 4,783 214.5%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   NOVARTIS  TORRENT PHARMA  DISHMAN PHARMA  STERLING BIOTECH  ASTRAZENECA PHARMA  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat; Metal and Telecom Stocks Witness Buying(Closing)

Indian share markets continued to trade on a volatile note and ended on a flat note today. At the closing bell, the BSE Sensex stood lower by 24 points (down 0.1%).

Related Views on News

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

More Views on News

Most Popular

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

My Best Trading Ideas When Interest Rates Are So Low(Fast Profits Daily)

Jul 23, 2020

India's interest rates are lower than the inflation rate. Here are the best trades for this situation.

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Gold or Silver: Which One Should You Buy Now?(Fast Profits Daily)

Jul 24, 2020

Silver and gold are both vying for your attention. Which is the better trade today?

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Aug 5, 2020 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS